ArticleThe Journal of infectious diseases2025
Prediction of Vancomycin Area Under the Curve With Trough Concentrations Only: Performance Evaluation of Pediatric Population Pharmacokinetic Models.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Feasibility of vancomycin AUCFrontiers in pharmacology · 2026Article
- Revised therapeutic window for vancomycin in pediatric patients: evidence from a retrospective therapeutic drug monitoring study.BMC pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn pediatric patients, vancomycin plays a pivotal role in combating infections, necessitating precise therapeutic drug monitoring to ensure efficacy and safety. The adoption of model-informed precision dosing (MIPD) has demonstrated potential in optimizing dosing strategies based on the 24-hour area under the concentration-time curve (AUC24h). However, the predictive performance of population pharmacokinetic models by using only trough concentrations to estimate AUC24h has not been evaluated.
methodsThe predictive performance of 23 vancomycin population pharmacokinetic models was retrospectively evaluated in 2 cohorts: cohort A, 21 patients with postnatal age <50 days; cohort B, 124 patients with postnatal age ≥50 days. Multiple scenarios were investigated by using peak and trough concentration, peak concentration solely, trough concentration solely, or covariate information (a priori). The median AUC24h per patient across all models was used as the true AUC24h.
resultsFor both cohorts, the relative root mean square error (rRMSE) for the AUC24h precision based on trough concentrations was similar to the rRMSE based on a peak and trough sample. For cohort A, the models by Chen, Colin, and Mehrotra showed the best trough-based performance with the lowest relative bias (range, -3.3% to -2.6%) and rRMSE (range, 6.8%-7.3%). For cohort B, the models from Alsultan and Lv illustrated the lowest relative bias (range, 1.75% to -5.4%) and rRMSE (range, 16.6%-15.1%).
conclusionsThis study illustrates that trough concentration-based AUC24h estimation is a feasible approach in vancomycin MIPD. These findings endorse the selected models for advanced MIPD vancomycin therapy in pediatrics, although further investigation into clinical outcomes is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.